Navigation Links
The Deal Names Abbott Top Dealmaker for Third Consecutive Year
Date:9/20/2010

d a licensing agreement with Zydus Cadila to promote a portfolio of pharmaceutical products in 15 high-growth emerging markets.
  • Acquired a novel investigational biologic compound to treat chronic pain, enhancing Abbott's early-stage pharmaceutical pipeline.
  • Announced a collaboration with Neurocrine and Pierre Fabre to develop and commercialize treatments for endometriosis and oncology, respectively.

  • The Deal's readers rated Abbott best on the award criteria: choice of targets and strategy; price paid (or received) compared to value; execution, including integration; and overall quality of the deal team.  Companies considered for the survey have a market capitalization of $5 billion or more as of Dec. 31, 2009, closed the highest number and value of transactions and generated the largest increase in market capitalization over a three-year period ended Dec. 31, 2009.  

    About The Deal LLCThe Deal LLC (www.TheDeal.com) is a diversified media and information company. We report, analyze and disseminate business and financial news and data that offer fresh insights on the deal economy, a set of interrelated activities, focused on dealmaking of all kinds, whose purpose is to generate corporate and capital growth in a continually changing global market. We serve the global deal community – corporate and financial dealmakers, advisers and institutional investors – with The Deal Pipeline, a transaction information service, and The Deal magazine, a business and financial magazine, website and event brand. The Deal LLC, a privately held company, is owned by private investment funds sponsored by Wasserstein & Co. LP.  

    About AbbottAbbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.  The company employs
    '/>"/>

    SOURCE Abbott
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Intarcia Therapeutics Names Kurt Graves Executive Chairman to Advance Strategic Interests and Broaden Commercial Goals
    2. FierceBiotech Names VentiRx Pharmaceuticals as One of the Fierce 15 Biotech Companies of 2010
    3. Windhover Information Names D-Tagatose One of Top 10 Most Promising CV/Metabolic Drugs in Development
    4. FierceBiotech Names Obesity Company Gelesis to Fierce 15 List of Top Emerging Biotech Companies
    5. AAIPharma Services Corp. Names Patrick Walsh Chief Executive Officer
    6. INC. 5000 Names ClinixMIS for Third Time
    7. SL Industries Names Louis J. Belardi Chief Financial Officer
    8. BayCare Health System Names Tim Thompson Chief Information Officer
    9. Watson Names Sigurdur Oli Olafsson Executive Vice President, Global Generics
    10. K-V Pharmaceutical Names Thomas McHugh Chief Financial Officer
    11. Ikaria® Names New Chief Financial Officer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... 21, 2014 Abaxis, Inc. (NasdaqGS: ... analysis systems, today reported financial results for the second ... quarter overview: , Revenues of $53.9 million, up ... EPS of $0.24, up 33% over last year,s comparable ... from Abaxis Veterinary Reference Laboratories (AVRL) of $3.5 million, ...
    (Date:10/22/2014)... VIEW, Calif. , Oct. 22, 2014 ... a.m. EDTLOCATION: Online, complimentary registration available at: ... Team Leader Archana Vidyasekar and Visionary Innovation ... computers, WiFi-like wireless electricity, self-assembling materials, nanobots ... ten technologies which will transform our lives ...
    (Date:10/22/2014)... 22, 2014  Regulus Therapeutics Inc. (NASDAQ: ... leading the discovery and development of innovative ... has demonstrated human proof-of-concept with a microRNA ... RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ... virus infection ("HCV").  Interim results from the ...
    Breaking Medicine Technology:Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
    ... (NYSE: VAR ) will showcase radiosurgery technologies ... non-invasively at the 2012 International Conference of the American ... "We,re excited about putting our technology ... with radiosurgery as a treatment option for early-stage, inoperable ...
    ... 2012 OrbusNeich today announced that two subgroup ... of the company,s Combo Dual Therapy Stent versus ... with the Combo Stent.  Presented at EuroPCR 2012, ... tomography (FD-OCT) and virtual histology-intravascular ultrasound (VH-IVUS) at ...
    Cached Medicine Technology:Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer 2Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer 3Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer 4Early Coronary Artery Healing Advantage of OrbusNeich's Combo Dual Therapy Stent™ Compared to the TAXUS® Stent Shown in Two Clinical Trial Subgroup Analyses 2Early Coronary Artery Healing Advantage of OrbusNeich's Combo Dual Therapy Stent™ Compared to the TAXUS® Stent Shown in Two Clinical Trial Subgroup Analyses 3Early Coronary Artery Healing Advantage of OrbusNeich's Combo Dual Therapy Stent™ Compared to the TAXUS® Stent Shown in Two Clinical Trial Subgroup Analyses 4
    (Date:10/22/2014)... Losing Weight Your Body’s Way , In ... in the face, it certainly can be difficult to choose ... an extra favor by doing it the healthy way? Set ... listen to your body, exercise regularly, and choose foods with ... losing weight; you need to exercise more and eat less. ...
    (Date:10/22/2014)... Lintelus, Inc., an event software provider, announced ... will be speaking on the subject of “Event Technology ... 28, at the Holiday Inn in New York City. ... as a Tech Demo at 12:45pm, to educate event ... engaging event experience. , The Annual Meetings Technology Expo ...
    (Date:10/22/2014)... Akeso Biomedical, Inc. , a privately ... bacterial infections, microbial biofilms, and chronic wounds, announced that ... directors. , Dr. Sinskey is a ... Institute of Technology, or MIT. He has been a ... also holds positions as Co-Director of the Malaysia-MIT Biotechnology ...
    (Date:10/22/2014)... Salamon HealthDay Reporter , TUESDAY, ... vitro fertilization (IVF) are only about half as likely as ... technique, new research indicates, and the racial disparity persists even ... 31 percent of white patients became pregnant after IVF, compared ... than 4,000 IVF cycles over two years to tease out ...
    (Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... to increased blood pressure, according to a new study. ... pressure for young adult women or for teenagers, according to ... or moderately, their risk of high blood pressure was cut ... in older adult men and women," said lead researcher Dr. ...
    Breaking Medicine News(10 mins):Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4
    ... eggs to deteriorate in quality with age, and can that ... egg -- out of a stash of roughly one million ... be influenced to pick a "good" quality egg rather than ... much on the mind of fertility researcher Teresa Woodruff. Woodruff, ...
    ... a key protein might reap rewards for people ... (HealthDay News) -- Researchers have uncovered cellular proteins that ... according to a new study. , The findings, ... new treatments for a range of human diseases that ...
    ... WASHINGTON, June 19 Most seniors -,regardless ... Medicare or Medicare,Advantage - oppose cutting the ... payment fix and believe cuts to Medicare ... a new survey finds., Power Point ...
    ... Protections for Poor Beneficiaries, SAN FRANCISCO, June ... federal court today in the Medicare Part D ... has agreed to make,significant changes to its administration ... approved by the judge, the agreement will,make it ...
    ... DALLAS, June 19 Federal Reserve chairman Ben Bernanke,s,comments ... health care,system is one of the biggest challenges facing ... care costs will rise nearly 10 percent this,year, lend ... emphasis on,prevention and wellness, according to U.S. Preventive Medicine, ...
    ... Better Health offers members access to 75 generic drugs at no cost ... ... Independence Blue Cross (IBC),will waive copays and coinsurance on 75 generic drugs ... a member incentive,program designed to help our members become more actively involved ...
    Cached Medicine News:Health News:New photo 'op' for ovaries may solve some mysteries of infertility 2Health News:Autoimmune Disease Treatment May Not Dampen Immune System 2Health News:Autoimmune Disease Treatment May Not Dampen Immune System 3Health News:Autoimmune Disease Treatment May Not Dampen Immune System 4Health News:Seniors Oppose Cutting Medicare Advantage to Fund Physician Payment Fix 2Health News:Bush Administration Settles Nationwide Class Action in Medicare Prescription Drug Case 2Health News:Bush Administration Settles Nationwide Class Action in Medicare Prescription Drug Case 3Health News:U.S. Preventive Medicine Views Bernanke's Comments as Strong Support for Prevention and Wellness Programs 2Health News:Independence Blue Cross Waives Copays for Generics Used to Treat Certain Chronic Conditions 2Health News:Independence Blue Cross Waives Copays for Generics Used to Treat Certain Chronic Conditions 3Health News:Independence Blue Cross Waives Copays for Generics Used to Treat Certain Chronic Conditions 4
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: